Gliwiński Mateusz, Iwaszkiewicz-Grześ Dorota, Trzonkowski Piotr
Department of Clinical Immunology and Transplantology, Medical University of Gdańsk, Dębinki 7, 80-210, Gdańsk, Poland.
BioDrugs. 2017 Aug;31(4):335-347. doi: 10.1007/s40259-017-0228-3.
CD4CD25FoxP3 T regulatory cells (Tregs) are immunodominant suppressors in the immune system. Tregs use various mechanisms to control immune responses. Preclinical data from animal models have confirmed the huge therapeutic potential of Tregs in many immune-mediated diseases. Hence, these cells are now on the road to translation to cell therapy in the clinic as the first clinical trials are accomplished. To date, clinical research has involved mainly hematopoietic stem cell transplantations, solid organ transplantations, and autoimmunity. Despite difficulties with legislation and technical issues, treatment is constantly evolving and may soon represent a valid alternative for patients with diseases that are currently incurable. This review focuses on the basic and clinical experience with Tregs with adoptive transfer of these cells, primarily from clinical trials, as well as on perspectives on clinical use and technical problems with implementing the therapy.
CD4CD25FoxP3 调节性 T 细胞（Tregs）是免疫系统中占主导地位的免疫抑制细胞。Tregs 利用多种机制来控制免疫反应。来自动物模型的临床前数据已证实 Tregs 在许多免疫介导疾病中具有巨大的治疗潜力。因此，随着首批临床试验的完成，这些细胞目前正迈向临床细胞治疗阶段。迄今为止，临床研究主要涉及造血干细胞移植、实体器官移植和自身免疫性疾病。尽管在立法和技术问题上存在困难，但治疗方法仍在不断发展，可能很快成为目前无法治愈疾病患者的有效替代方案。本综述重点关注 Tregs 过继性转移的基础和临床经验，主要来自临床试验，以及临床应用前景和实施该疗法的技术问题。
